News

Invest Stock information News Corporate news Ad hoc releases Financial publications IR Events Annual General Meeting Corporate Governance

 

It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

Corporate news

Type
Year
all 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001
2020
Evotec and Indivumed announce second joint drug discovery programme
Hamburg, Germany, January 23, 2020

Evotec SE and Indivumed today announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer (“NSCLC”).

Just – Evotec Biologics announces product development and manufacturing agreement with OncoResponse
Hamburg, Germany, January 16, 2020

Evotec SE today announced that its wholly-owned Seattle-based subsidiary company Just – Evotec Biologics, Inc. has established a collaborative relationship with OncoResponse, Inc., a biotech company developing human antibodies as product candidates for multiple high value targets associated with immunosuppressive myeloid biology.

Just – Evotec Biologics initiates construction of first J.POD® facility in North America
Hamburg, Germany, January 14, 2020

Evotec SE today announced that the wholly-owned Seattle-based company Just – Evotec Biologics initiated the construction of a late-stage clinical and commercial manufacturing facility for biologics in Redmond, Washington.

Just – Evotec Biologics enters into multi-year collaboration with MSD around facility of the future
Hamburg, Germany, January 14, 2020

Evotec SE today announced that its wholly-owned Seattle-based subsidiary company Just – Evotec Biologics, Inc. has expanded its collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, regarding the development of innovative technologies for the production of biologics of the highest quality.

Bayer and Evotec form new strategic alliance focusing on polycystic ovary syndrome
Hamburg and Berlin, Germany, January 9, 2020

Evotec SE and Bayer AG today announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”).

Evotec and Bristol-Myers Squibb expand iPSC collaboration
Hamburg, Germany, January 7, 2020

Evotec SE announced today that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company following the decision to expand the collaboration to include additional cell lines.

Evotec to attend upcoming investor conferences
Hamburg, Germany, January 2, 2020

Evotec SE announced today that its management will be presenting at and attending investor conferences in January and February 2020.

 

Ad hoc releases

Please find below Evotec's most recent ad hoc releases according to Article 17 European Market Abuse Regulation (MAR).

 

Type
Year
all 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004
2020
Evotec SE: Increase of profitability guidance for financial year 2019
Hamburg, January 20, 2020

Evotec SE today announced an increase in its profitability guidance for the financial year 2019 after the preliminary completion of the latest evaluation of the Company's financial performance.

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec SE, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Downloads

Announcement pursuant § 62 (3) German Conversion Act (in German only)PDF, 15.8 KB

Draft of the merger agreement between Evotec AG and CCS Cell Culture Service GmbH (in German only)PDF, 31.7 KB

Contact us

Gabriele Hansen

SVP, Corporate Communications, Marketing & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Anja Ben Lekhal

Investor Relations Associate

T + 49 40 56081 210 F +49 40 56081 222 vCard
TOP